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AbstrACt
Objectives There is limited published research studying the 
effect of antibiotic prophylaxis on surgical site infection (SSI) 
in dermatological surgery, and there is no consensus for its 
use in higher-risk cases. The objective of this study was to 
determine the effectiveness of a single oral preoperative 2 g 
dose of cephalexin in preventing SSI following flap and graft 
dermatological closures on the nose and ear.
Design Prospective double-blinded, randomised, placebo-
controlled trial testing for difference in infection rates.
setting Primary care skin cancer clinics in North 
Queensland, Australia, were randomised to 2 g oral 
cephalexin or placebo 40–60 min prior to skin incision.
Participants 154 consecutive eligible patients booked for 
flap or graft closure following skin cancer excision on the 
ear and nose.
Intervention 2 g dose of cephalexin administered 40–
60 min prior to surgery.
results Overall 8/69 (11.6%) controls and 1/73 (1.4%) 
in the intervention group developed SSI (p=0.015; 
absolute SSI reduction 10.2%; number needed to treat 
(NNT) for benefit 9.8, 95% CI 5.5 to 45.5). In males, 7/44 
controls and 0/33 in the intervention group developed SSI 
(p=0.018; absolute SSI reduction 15.9%; NNT for benefit 
6.3, 95% CI 3.8 to 19.2). SSI was much lower in female 
controls (1/25) and antibiotic prophylaxis did not further 
reduce this (p=1.0). There was no difference between the 
study groups in adverse symptoms attributable to high-
dose antibiotic administration (p=0.871).
Conclusion A single oral 2 g dose of cephalexin given 
before complex skin closure on the nose and ear reduced 
SSI.
trial registration number ANZCTR 365115; Post-results.
IntrODuCtIOn  
Though limited published evidence is avail-
able to support or refute the use of oral anti-
biotic prophylaxis for prevention of surgical 
site infection (SSI) in dermatological surgery, 
several authorities suggest considering it for 
selected high-risk cases.1–4 
As the ears and noses are especially vulner-
able to ultraviolet (UV) radiation, generally 
being uncovered and protruding from the 
body, skin cancers are more commonly found 
at these sites than most other body sites.5 
Furthermore, the cancers that develop on 
the nose and ear are more likely to be of an 
aggressive subtype6 requiring wider excision 
margins and subsequent flap or graft surgical 
repair for optimal cosmetic and functional 
outcome. The body site and the need for 
complex closure put patients with auricular 
or nasal skin cancers at significantly higher 
risk of SSI than is normally observed for clean 
dermatological surgery.1–4
Despite the paucity of evidence for derma-
tological antibiotic prophylaxis, first-genera-
tion cephalosporins or penicillinase-resistant 
penicillins are generally recommended as 
Staphylococcus aureus and Streptococci are the 
most prevalent bacteria causing SSI.1 2 Oral 
cephalexin or dicloxacillin given as a 2 g oral 
dose 30–60 min before the procedure has 
been recommended by several authorities.1 2 7
The aim of this study was to determine 
whether the use of a single 2 g dose of 
strengths and limitations of this study
 ► Blinded randomised design with placebo control.
 ► Standardised protocols used for excision and 
follow-up.
 ► Low baseline infection rate in women meant under-
powered to draw conclusions for this subgroup.
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cephalexin given 40–60 min prior to surgery would signifi-
cantly reduce infection rates following complex auricular 
and nasal dermatological surgery.
MethOD
Consecutive eligible patients booked for flap or graft 
closure following skin cancer excision on the ear and 
nose were recruited by six doctors (including the prin-
cipal researcher HR) working at a primary care skin 
cancer clinic in Townsville, North Queensland, Australia, 
between December 2013 and March 2016. Study partici-
pation was allowed once only for each individual patient. 
All participants2 gave signed informed consent.
Specific exclusion criteria (figure 1) were aged under 
18, intellectual or mental impairment affecting ability to 
give informed consent, allergy to the protocol suture or 
dressing materials, allergy to cephalosporins or penicillin, 
use of any antibiotic (other than the intervention) within 
48 hours of the surgery and suspected SSI at the time of 
surgical closure. If pathology confirmed residual tumour 
and the need for a wider excision the participant was 
subsequently excluded from the study.
All participants presented 30 min prior to their surgery 
for administration of capsules containing either 2 g ceph-
alexin or a placebo. The initial skin incision was made 
40–60 min after ingestion of capsules. Cephalexin was 
used because it has an antistaphylococcal activity and 
therefore covers organisms most likely to cause wound 
infection, but can be used in most patients with penicillin 
allergy and is cheaper than flucloxacillin.2 Pharmacoki-
netic data show average peak dose serum levels of approx-
imately 19 µg/mL at 1 hour following a 500 mg dose.8 A 
2 g dose has been used effectively in previous studies.8 
Baseline demographic data, relevant medical and drug 
history, histology, defect size, time from intervention to 
surgery and closure technique were documented at the 
time of surgery.
Modified Mohs micrographic surgery
We used an adaptation of classical Mohs micrographic 
surgery (MMS) for patients with biopsy-proven aggressive 
tumours that had indistinct margins or were 10 mm or 
larger. The wound was left open under a dressing for 2 
days awaiting complete histological deep and peripheral 
margin analysis using traditional H&E staining of wax-em-
bedded samples in a pathology laboratory. Further exci-
sion and detailed histological analysis was undertaken 
if required with the wound only being closed once 
histology confirmed complete excision. It is known that 
SSI following secondary intention healing is very low,9 10 
hence antibiotic or placebo was only given prior to the 
actual flap or graft wound closure.
Intraoperative and postoperative protocol
Nylon sutures (Dynek, Hendon, South Australia) were 
used superficially for all defect closures. Where deep 
dermal absorbable sutures were deemed necessary, 
Monosyn (B Braun Australia) was used. Melolin (Smith 
and Nephew Medical, Hull, UK) and Fixomull (BSN 
Medical Luxembourg) were applied to wounds  imme-
diately after surgery. Participants were asked not to use 
topical creams, ointments or antiseptics on their wounds 
postoperatively and were given standardised written and 
verbal instructions on postoperative wound care. Early 
wound review was encouraged in the event of any partici-
pant concern. Sutures were removed 5–7 days postopera-
tively. Any wound that had not fully healed was redressed 
until the defect had fully epithelialised.
Figure 1 Inclusion and exclusion criteria.
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Clinical outcome
Though there is no validated gold-standard definition for 
SSI, the 1988 Centers of Disease Control and Prevention 
of National Nosocomial Infections Surveillance System 
definition11 has been widely adopted in Australia, USA 
and Europe. We used an adapted version of this defini-
tion (figure 2). The superficial surgical site skin infection 
had to occur within 30 days of surgery and at least one 
of the following wound characteristics had to be present:
a. purulent discharge
b.  localised swelling, pain or heat
c. erythema >1 cm from wound edges
d. patient report of increasing tenderness.
Using this classification, if SSI was suspected by the 
treating doctor a swab was taken for microbiology culture 
and sensitivity and a 5-day course of cephalexin (500 mg 
four times per day) prescribed pending swab results.
The study nurse phoned participants 1 month postop-
eratively to cross-check if Dermatological Surgical Site 
Infection (DSSI) or any other complication had occurred 
helping to ensure that this had not been inadvertently 
missed.
randomisation and blinding
The randomisation sequence, generated off-site elec-
tronically by author and statistician PGB, was sent to a 
compounding pharmacy in Townsville. Here batches of 
generic gel capsules were filled with either cephalexin 
(intervention) or microcrystalline cellulose and calcium 
carbonate (placebo) and sent to the recruiting practice 
in small screw top containers numbered according to 
the randomisation sequence. Each numbered container 
held four identical-looking gel capsules filled with either 
500 mg cephalexin or placebo. Staff and participants at 
the recruiting clinic remained blinded to group alloca-
tion until the study had been completed.
sample size
The infection rate for complex auricular and nasal 
dermatological surgery in a small observational survey 
at out clinic prior to commencing this study was around 
20%. Our hypothesis was that antibiotic prophylaxis 
would reduce SSI fivefold from 20% to 4%. To show this 
with statistical confidence (power in excess of 80%; signif-
icance level 0.05), 59 patients were required in each study 
group. Allowing for a 20% drop-out it was planned to 
recruit 142 participants (71 intervention and 71 placebo).
statistical analysis and presentation
Numerical data were described using mean and SD when 
symmetrically distributed and median and IQR when 
skewed. Categorical data were presented using absolute 
and relative frequencies.
Eligible non-participants were compared with partic-
ipants using unpaired t-test, χ2 and Fisher’s exact test. 
Intervention and control group differences at baseline 
as well as treatment modality differences were assessed 
using unpaired t-test, Mann-Whitney U test, χ2 and Fish-
er’s exact test.
The main analysis comparing intervention and control 
groups with regards to SSI was modified by intention-to-
treat (ITT) analysis based on available cases at follow-up 
and adhered to Consolidated Standards of Reporting 
Trials (CONSORT) guidelines.12 Furthermore, ITT anal-
ysis was conducted assuming that: (1) none of the lost 
to follow-up cases had developed SSI and (2) all lost to 
follow-up cases had developed SSI.
Incidence of wound infection was compared between 
intervention and control groups using Fisher’s exact test. 
The differences in infection rates and number needed to 
treat for benefit (NNTB) were calculated with 95%  CIs.13
χ2 test and Fisher’s exact test were used to compare 
postoperative complications, adverse effects and treat-
ment of established postoperative infections between 
intervention and control groups.
Analysis was conducted using SPSS V.21 (IBM SPSS). A 
significance level of 0.05 was assumed. All statistical tests 
were conducted two sided.
results
Of 199 consecutive patients requiring flap or graft closures 
on the nose or ear, 20 were ineligible due to penicillin or 
cephalosporin allergy (11), intellectual impairment (4) 
or taking antibiotics for other reasons within 48 hours of 
their skin surgery (5). See figure 3 for CONSORT flow 
diagram.
Twenty-five eligible patients opted not to participate 
most commonly as they were unwilling to take unneces-
sary medication (14). Other reasons for non-participa-
tion (11) included fear of diarrhoea or allergy, difficulty 
swallowing tablets and not having time to come in 30 min 
ahead of the scheduled appointment.
Inadvertently, 12 more participants were recruited 
than planned resulting in a total of 154 participants. The 
participants were slightly older (mean age 66.3 years) and 
more likely to be female (71, 46.1%) than the 25 eligible 
non-participants (mean age 63.2 years; 8 female). Other-
wise no difference was found between participants and 
non-participants (table 1).
Four participants violated protocol because of the need 
for a wider excision (1) or the doctor or patient changing 
their mind about having flap or graft surgery after the 
Figure 2 Criteria for surgical site infection.
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antibiotic or placebo had been given (3). Due to death 
from unrelated causes during the postoperative study 
period (1) or failure to respond to repeated telephone 
follow-up (7) eight participants were lost to follow-up. 
These 12 participants who did not complete the study as 
intended (table 2) were more likely to be smokers (3) or 
study controls (8) than participants who did complete the 
study.
Table 3 shows that the randomisation was mostly 
successful creating comparable groups at baseline. 
However, there were more male patients in the control 
group (63.8% vs 45.2%).
surgical site infection
The main analysis based on available cases at follow-up 
(table 4) showed that one (1.4%; n=73) SSI occurred 
in the intervention group compared with eight (11.6%; 
n=69) in the control group (p=0.015).
The difference in incidence of infection was 10.2% 
(95% CI 2.2% to 18.2%). The NNTB was 9.8 (95% CI 
5.5 to 45.5). These results were confirmed by the ITT 
analyses (table 5) assuming both that (1) none of the 12 
cases lost to follow-up had developed SSI (p=0.034) and 
(2) all 12 cases had developed SSI (p=0.017).
ssI-stratified analysis by sex
Giving cephalexin prior to surgery significantly reduced 
SSI in men (table 4) with 7 of the 44 controls and none 
of the 33 intervention participants developing infection 
(p=0.018). Antibiotic prophylaxis resulted in an abso-
lute SSI reduction of 15.9% (95% CI 5.2% to 26.6%) 
and a relative SSI reduction of 100% in men. In order to 
prevent one infection in male participants, 6.3 men need 
to be treated (95% CI 3.8 to 19.2).
Antibiotic prophylaxis made no difference to the low 
rate of SSI in women with one control (n=25) and one 
Figure 3 Consolidated Standards of Reporting Trials flow chart references.   
Table 1 Comparison of participants with non-participants 
who fulfilled inclusion criteria
Characteristic
Participants 
(n=154)
Eligible patients 
who did not 
participate 
(n=25)
Mean age (SD) (years) 66.3 (11.1) 63.2 (12.2)
Female n=71 (46.1%) n=8 (32.0%)
Histology of lesion
  BCC n=117 (76.0%) n=20 (80.0%) 
  SCC n=16 (10.4%) n=3 (12.0%) 
  IEC n=20 (13.0%) n=2 (8.0%) 
  Dysplastic naevus n=1 (0.6%) n=0 
Body site of lesion
  Nose n=108 (70.1%) n=15 (60.0%) 
  Ear n=46 (29.9%) n=10 (40.0%) 
Smoker n=13 (8.4%) n=1 (4.0%)
Diabetes mellitus n=18 (11.6%) n=2 (8.0%)
User of anticoagulant 
medication
n=38 (24.7%) n=7 (28.0%)
User of 
immunosuppressive 
medication
n=2 (1.3%) n=0
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intervention participant (n=40) developing infection 
(p=1.0).
Regardless of group allocation, none of the partic-
ipants who had modified MMS (delayed closure 
following complete histological margin analysis) devel-
oped SSI.
swab results for ssI cases
For the nine participants who developed SSI (table 6), 
eight had swabs taken for microscopy, culture and 
sensitivity.
Cephalexin-sensitive S. aureus was confirmed in six 
participants. In one participant cephalexin-resistant 
Hafnia alvei infection was confirmed; the infection had 
already responded clinically to prescribed cephalexin by 
the time the microbiology report was available. Pseudo-
monas aeruginosa was confirmed in a control participant 
following an ear wound repair; this settled quickly once 
antibiotics were changed to the quinolone ciprofloxacin 
in accordance with culture sensitivity. The final partici-
pant with SSI inadvertently attended his general practi-
tioner who prescribed flucloxacillin without taking a swab 
for culture and sensitivity. At the time of suture removal 
at the study practice, review of a photograph taken by 
the participant before antibiotics had been prescribed 
confirmed SSI clinically.
secondary outcome measures
With respect to postoperative complications other than 
infection (table 7), there was no difference between the 
study groups (p=0.364) with two postoperative haemor-
rhages (both intervention), one flap necrosis (control) 
and one wound dehiscence (intervention).
Furthermore, there was no significant difference 
between the study groups in adverse symptoms (table 7) 
that might have been attributable to high-dose antibiotic 
administration (p=0.871) with one participant from each 
study group suffering some nausea and mild diarrhoea 
being reported in one intervention participant.
DIsCussIOn
Though infection rates are generally very low for clean 
dermatological surgery,1–3 a significant increase in SSI is 
observed for surgery on the ear and nose compared with 
other body sites.14–16 Of all body sites the nose and ear have 
the greatest concentration of sebaceous glands. With the 
latter being heavily colonised by bacteria, the increased 
Table 2 Comparison analyses of participants who 
completed the study to those who did not complete the 
study
Characteristic
Participants 
completing 
study (n=142)
Participants not
completing 
study (n=12)
Control group n=69 (48.6%) n=8 (66.6%)
Mean age (SD) (years) 66.2 (11.1) 67.5 (11.2)
Male n=77 (54.2%) n=6 (50.0%)
Histology of lesion
  BCC n=107 (75.4%) n=10 (83.3%) 
  SCC n=15 (10.6%) n=1 (8.3%) 
  IEC n=19 (13.4%) n=1 (8.3%) 
  Dysplastic naevus n=1 (0.7%) n=0 
Body site of lesion
  Nose n=100 (70.4%) n=8 (66.7%) 
  Ear n=42 (29.6%) n=4 (33.3%) 
Smoker n=10 (7.0%) n=3 (25.0%)
Diabetes mellitus n=16 (11.3%) n=2 (16.7%)
User of anticoagulant 
medication
n=36 (25.4%) n=2 (16.7%)
User of 
immunosuppressive 
medication
n=2 (1.4%) n=0
Median time to surgery 
(IQR) (min)
50 (45–55) 45 (36.25–50)
Table 3 Baseline comparison of intervention group (n=73) 
with control group (n=69)
Characteristic
Intervention 
group (n=73)
Control group 
(n=69)
Mean age (SD) (years) 66.6 (11.5) 65.9 (10.8)
Male n=33 (45.2%) n=44 (63.8%)
Histology of lesion
  BCC n=55 (75.3%) n=52 (75.4%) 
  SCC n=7 (9.6%) n=8 (11.6%) 
  IEC n=10 (13.7%) n=9 (13.0%) 
  Dysplastic naevus n=1 (1.4%) n=0 
Body site of lesion
  Nose n=55 (75.3%) n=45 (65.2%) 
  Ear n=18 (24.7%) n=24 (34.8%) 
Smoker n=4 (5.5%) n=6 (8.7%)
Diabetes mellitus n=8 (11.0%) n=8 (11.6%)
Anticoagulant medication n=19 (26.0%) n=17 (24.6%)
Immunosuppressive 
medication
n=1 (1.4%) n=1 (1.4%)
Median time to surgery 
(IQR) (min) 
50 (45–55) 50 (45–55)
Modified MMS* n=10 (13.7%) n=12 (17.4%)
Surgical repair technique
  Flap repair n=68 (94.5%) n=58 (88.4%) 
  Skin graft n=3 (4.1%) n=6 (8.7%) 
  Wedge excision n=1 (1.4%) n = 2 (2.9%) 
Median defect size (IQR); 
range (mm)
13 (11.5–16); 
9–25
14 (12–16.5); 
9–30
*Delayed surgical closure awaiting complete histological margin 
analysis.
MMS, Mohs micrographic surgery.
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risk of SSI on the nose and ear may be explained. Further-
more, with the nares being a principal source of S. aureus, 
it is postulated that its proximity puts nasal skin incisions 
at higher risk of infection still.
Complex wound closures have consistently been linked 
with greater risk of SSI than simple closures.14 16–19 In a 
large prospective study involving 3491 surgical derma-
tological procedures, Rogues et al observed that the 
difference in infection rates following flap and graft 
closure (14.7%) rather than simple closure (1.7%) was 
even more marked when clean rather than sterile gloves 
were worn.19 For complex dermatological closures also 
involving the nose and ear, Sylaidis et al found a much 
higher infection rate (6 of 27) than they did for complex 
skin closures elsewhere on the face (3 of 43).14
The evidence to support or refute the use of oral antibi-
otic prophylaxis for dermatological surgery at higher risk 
of SSI is scant.3 20 21 Though overt infection was seen in 
none of 30 randomised controlled trial (RCT) patients 
undergoing full thickness graft reconstruction surgery 
on the nose, Kuijpers et al found the graft survival was 
better for those randomised to antibiotic prophylaxis 
(azithromycin for 3 days).22 Subanalysis of 60 reconstruc-
tive dermatological flap procedures in an RCT confirmed 
that antibiotic prophylaxis resulted in significantly fewer 
SSIs.23 In a small non-randomised observational study 
involving 18 patients having facial graft surgery for Non 
Melanotic Skin Cancer (NMSC), Saleh et al observed that 
antibiotic prophylaxis resulted in significantly less infec-
tion, graft loss and graft necrosis.24 Conversely, in an RCT 
involving 82 patients undergoing secondary intention 
healing following auricular Mohs surgery, Mailler-Savage 
et al found no difference in wound healing or SSI with 
antibiotic prophylaxis (levofloxacin).25
In our RCT for patients having complex cutaneous 
repair on the nose and ear, a significant reduction in SSI 
was found following antibiotic prophylaxis. Although our 
baseline infection rate was lower than anticipated (11.6% 
Table 4 SSI analysis of available cases, stratified by sex
Antibiotic 
Prophylaxis
Control 
group P values
Absolute risk 
reduction 95% CI
Relative risk 
reduction (%) NNTB (95% CI)
Analysis of available cases
n=73 n=69
  No of SSI n=1 n=8
  Incidence rate of SSI 1.4% 11.6% P=0.015* 10.2% 2.2 to 18.2 87.9 9.8 (5.5 to 45.5)
Analysis of available cases stratified by sex
Male n=33 n=44
  Incidence rate of SSI 0%
(n=0)
15.9% 
(n=7)
P=0.018* 15.9% 5.2 to 26.6 100 6.3 (3.8 to 19.2)
Female n=40 n=25
  Incidence rate of SSI 2.5%
(n=1)
4.0%
(n=1)
P=1.0* 1.5% −7.6 to 10.6 37.5 66.7 (NNTH 13.2 
to infinity to NNTB 
9.4)
*P values are results of Fisher’s exact test.
NNTB, number needed to treat for benefit; NNTH, number needed to treat for harm; SSI, surgical site infection.
Table 5 SSI analysis by ‘ITT’ assuming (1) all and (2) none of the participants violating protocol or lost to follow-up would 
have developed SSI
Antibiotic 
Prophylaxis
Control 
group P values
Absolute risk 
reduction 95% CI
Relative risk 
reduction (%) NNTB (95% CI)
Analysis by ITT: assuming all the participants violating protocol or lost to follow-up would have developed SSI
n=77 n=77
No of SSI n=1 n=8
Incidence rate of SSI 1.3% 10.4% P=0.034* 9.1% 1.8 to 16.4 87.5 11.0 (6.1 to 
55.6)
Analysis by ITT: assuming none of  the participants violating protocol or lost to follow-up would have developed SSI
n=77 n=77
No of SSI n=5 n=16
Incidence rate of SSI 6.5% 20.8% P=0.017* 14.3% 3.7 to 24.9 68.8 7.0 (4.0 to 27.0)
*P values are results of Fisher’s exact test.
ITT, intention-to-treat; NNTB, number needed to treat for benefit; NNTH, number needed to treat for harm; SSI, surgical site infection.
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rather than 20%), the study was still adequately powered 
to assess the effect of antibiotic prophylaxis as the inter-
vention group had more than the fivefold reduction in 
infection rate (to 1.4%) that had been anticipated for the 
purpose of sample size calculation.
Our main analysis is presented as an available case 
analysis. The Cochrane definition of ITT is the analysis 
of all randomised participants even if they have violated 
the protocol or been lost to follow-up. We, therefore, 
imputed data for the 12 participants for whom we had 
been unable to collect outcome data (table 5). Our 
results remained significant regardless of whether those 
violating protocol and lost to follow-up had all developed 
SSI or all remained free of infection.
As sex was identified as a confounder, the analysis was 
stratified by sex. The benefit of antibiotic prophylaxis was 
clear in men. Just one of the 25 female controls developed 
SSI. The authors consider this too low an infection risk 
to justify routine antibiotic prophylaxis. Furthermore, no 
reduction in SSI was observed in the 40 women given anti-
biotic prophylaxis. It needs to be acknowledged, however, 
that due to the low baseline infection rate in women, the 
study was underpowered to draw conclusions regarding 
the effect of antibiotic prophylaxis in this subgroup.
Rogues et al also found that gender was an independent 
risk factor for SSI following complex reconstructive skin 
surgery with 6.3% of men and 1.1% of women developing 
infection.19 Men are known to have higher sebum produc-
tion and thicker skin than women particularly following 
menopause.26 The higher concentration of pilosebaceous 
units on the thicker glabrous skin of the ear and nose in 
men may mean an increased bacterial skin commensal 
load at these sites explaining the marked gender differ-
ence in SSI found in our study.
With no difference between the study groups in adverse 
symptoms that might have been attributable to the 
administration of a single high-antibiotic dose, our study 
confirms that 2 g oral cephalexin is well tolerated. Other 
studies have confirmed that higher-dose short-term anti-
biotics have no increased side effects compared with 
lower dose longer-term antibiotic courses.27
Though higher infection rates have been observed 
following MMS on the nose than other body sites,16 studies 
confirm that SSI is generally low following MMS.2 28 29 
The modified MMS we used, leaving wounds open under 
a dressing for up to 48-hour awaiting histology, was not 
associated with any increase in SSI compared with wounds 
closed immediately following excision.
COnClusIOn
With indiscriminate use of antibiotics causing the emer-
gence of ever more antibiotic-resistant pathogens, 
antibiotics should always be prescribed with caution. 
Table 6 Details of participants that developed SSI
Gender Study group Body site
Modified
MMS*
Surgical 
repair
Other 
complications
Organism isolated 
on swab MC&S
Sensitivity to 
cephalexin
Male Control Ear No Graft Nil Staphylococcus 
aureus 
Yes
Male Control Ear No Graft Nil S. aureus Yes
Male Control Nose No Flap Nil Hafnia alvei No
Male Control Ear No Flap Nil S. aureus Yes
Male Control Ear No Flap Nil S. aureus Yes
Male Control Nose No Flap Nil S. aureus Yes
Male Control Nose No Flap Nil GP without swab Unknown
Female Control Nose No Flap Nil S. aureus Yes
Female Intervention Ear No Flap Nil Pseudomonas 
aeruginosa
No
*Delayed surgical closure awaiting complete histological margin analysis.
GP, general practitioner; MC&S, Microscopy, Culture and Sensitivity; MMS, Mohs micrographic surgery; SSI, surgical site infection.
Table 7 Comparison of study groups with respect to 
postoperative complications and adverse events
Outcome 
characteristic
Antibiotic
prophylaxis 
(n=73)
Control 
group 
(n=69) P values
Complications P=0.364*
  None n=70 (95.9%) n=68 
(98.6%) 
  Bleeding 
postoperatively 
n=2 (2.7%) n=0 
  Flap necrosis n=0 n=1 (1.4%) 
  Wound 
dehiscence 
n=1 (1.4%) n=0 
Adverse events P=0.871*
  None n=71 (97.3%) n=68 
(98.6%) 
  Nausea n=1 (1.4%) n=1 (1.4%) 
  Diarrhoea n=1 (1.4%) n=0 
*P values are results of Fisher’s exact test.
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Open Access 
Where antibiotic prophylaxis has been shown to be 
both warranted and effective its use preoperatively may 
be justified. Furthermore, antibiotic resistance may be 
less likely following a single high-antibiotic prophylactic 
dose than following prolonged antibiotic treatment of an 
established infection.
In our study, an unacceptably high rate of SSI was 
observed following complex auricular and nasal derma-
tological repair. A single high-dose preoperative oral anti-
biotic significantly reduced SSI. The effect was significant 
in men but not women. Additionally, a bolus oral dose of 
2 g cephalexin dose was well tolerated with no measurable 
increase in adverse effects compared with placebo.
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